Earnings call: Mersana Therapeutics reports on ADC development progress By Investing.com

Published on 29 Feb 2024 on Investing.com

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ:MRSN) has provided updates on its antibody-drug...

Read the rest of the article

Start tracking your investments with Statfolio

Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

On October 11, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) executed a significant...

GuruFocus.com · via Yahoo Finance 15 Oct 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) just released its quarterly report and things are lookin...

Simply Wall St. via Yahoo Finance 10 May 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript May 9, 2024 Mersana The...

Insider Monkey via Yahoo Finance 10 May 2024

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ: MRSN ) has provided updates on its antibody-drug...

Investing.com 1 Mar 2024

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ:MRSN) has provided updates on its antibody-drug...

Investing.com 29 Feb 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript February 28, 2024 Mersa...

Insider Monkey via Yahoo Finance 29 Feb 2024

Shares of Butterfly Network, Inc. BFLY fell sharply during Thursday’s session after the company...

Benzinga 29 Feb 2024

Key Insights Mersana Therapeutics' estimated fair value is US$6.60 based on 2 Stage Free Cash Flo...

Simply Wall St. via Yahoo Finance 29 Feb 2024

Investing.com 28 Feb 2024